The authors determined three high-resolution (1.97β1.98 Γ ) co-crystal structures of EV68-3C protease bound to rupintrivir (PDB 8W3C), AG7404 (8W3M), and GC-376 (8W3T), all in space group P3121 with clear electron density for full inhibitors . Enzymatic assays showed rupintrivir most potent (IC50 0.0078 Β΅M), followed by AG7404 (0.0235 Β΅M), GC-376 (0.194 Β΅M), and PF-00835231 (1.8 Β΅M); nirmatrelvir and ensitrelvir showed no inhibition even at 10 Β΅M β a notable negative result given nirmatrelvir's nanomolar potency against SARS-CoV-2 Mpro, attributed to the bulky bicyclic proline at P2 .
Three findings stand out: (1) the catalytic His40 adopts three distinct conformations across co-crystals solved under identical crystallization conditions, contradicting the prior attribution of His40 conformers to pH differences ; (2) a structural water molecule capping the S1 pocket (coordinating Thr142, Asn165, Gly166, Gln168) appears in all ligand-bound EV68-3C structures and homologous enterovirus 3C structures, but is absent in apo structures β a conserved, targetable feature ; (3) substrate-envelope analysis predicts resistance-vulnerable protrusions at S1 (Gly166/Ala144), S2/S3 (Gly128), and S4 (Asn165), with GC-376 predicted to have a higher resistance barrier than rupintrivir or AG7404 .
The structural work is rigorous (Rfree 0.23β0.24, zero Ramachandran outliers, His-tag packing verified not to perturb active-site binding via comparison with tag-free 7L8H) . However, several limits warrant skepticism: resistance predictions rest entirely on crystallographic envelope inference β no reverse genetics or resistance-selection experiments in replicating virus were performed; nirmatrelvir's failure to inhibit despite MD-predicted stability reveals a disconnect between the authors' computational prescreen and experiment, undermining confidence in MD-based inhibitor selection; and the "higher resistance barrier" ranking of GC-376 is a hypothesis, not a measured quantity. The in vitro FRET assay uses a single substrate (2C/3A site), and cell-based antiviral or pharmacokinetic data are absent, so potency-to-therapeutic translation remains unestablished. The claimed conflict-free status and lack of listed funding leave provenance transparent but funding sources unstated.
Interactive view: rupintrivir-bound EV68-3C protease (PDB 8W3C).
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.